|
|
|
|
|
|
|
|
|
|
Abstract
Clinical Commentary
Highlights (no other information except as below without paid subscription)
- •
- Treananib targets angiogenesis by inhibiting angiopoietin 1 and 2.
- •
- A rare complication of trabananib is edema.
- •
- The proposed mechanism as well as the diagnosis and management of edema are discussed.
~~~~~~~~~~~~~~~~~~
Cancer Chemother Pharmacol. 2013 January; 71(1): 227–235.Published online 2012 November 3. doi: 10.1007/s00280-012-2000-1Phase 1 study of trebananib (AMG 386), an angiogenesis targeting angiopoietin-1/2 antagonist, in Japanese patients with advanced solid tumors
"....In the efficacy analysis, trebananib showed evidence of antitumor activity. Two patients, one with colon cancer and the other with bladder cancer, achieved a partial response. Both of them had a durable partial response and were on treatment at the time of data cutoff. In the previous single-agent study conducted in the United States, of 29 patients with evaluable tumor response, one patient with advanced ovarian cancer refractory to multiple chemotherapies had a partial response with the dose of 30 mg/k.....These results suggest the absence of ethnic difference......Conflict of interest
This study was sponsored by Takeda Bio Development Center Ltd. Kazuhiro Shibayama and Takatoshi Takubo are employees of Takeda Bio Development Center Ltd. David M. Weinreich was an employee as leadership position and owned stock of Amgen Inc. The other authors have no conflict of interest.
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.